CliffBio
biologic

encelto

revakinagene taroretcel-lwey

Loss of exclusivityMarch 2037FDA regulatory exclusivity expiry
CompanyNeurotech Pharmaceuticals, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameencelto
Active ingredientrevakinagene taroretcel-lwey
Strength200,000-440,000CELLS/IMPLANT
Dosage formImplant
RouteImplantation
ModalityBiologic
FDA approvalMarch 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

encelto patent cliff — loss of exclusivity March 2037 | CliffBio